Multinational phase 3 trial of fixed-duration ibrutinib-venetoclax in patients with CLL and comorbidities

Chronic lymphocytic leukemia is a disease that primarily affects elderly individuals, with chemoimmunotherapy historically serving as standard first-line therapy. While chlorambucil-obinutuzumab has been a first-line treatment for elderly and comorbid patients without TP53 alterations, it requires cumbersome infusions, and remission durations are suboptimal in many patients. The multinational phase 3 GLOW trial compared the all-oral, once daily, fixed duration ibrutinib-venetoclax regimen versus chlorambucil-obinutuzumab as first-line CLL treatment in older patients and/or those with comorbidies. Ibrutinib-venetoclax demonstrated superior PFS and better sustained responses versus chlorambucil-obinutuzumab.